Inequality, Democracy and the New Human Biotechnologies
By Richard Hayes
| 07. 15. 2004
Presentation at Inequality, Democracy and the New Human Biotechnologies: A Threshold Challenge for the 21st Century, New York, NY [PDF Version]
The new technologies of human genetic modification are among
the two or three most profoundly consequential technologies
of the 21st century. They have the potential for both great
good and great harm. They are being developed at an extraordinary
pace. There is little public oversight and control of their
development and use.
If these technologies are developed and used in the prevailing
context of free-market competition and individualist social
values, they could greatly exacerbate existing inequalities
in health and social power, and existing modes of discrimination
and exploitation. In addition, certain applications of these
technologies could open the door to a new high-tech eugenics
that would undermine the foundations of democratic civil society.
The dynamics of inequality, democracy and the new human biotechnologies
works the other way as well: at this moment, inequalities of
power and influence are themselves subverting democratic decision-making
concerning the development and use of the new human biotechnologies.
Surveys show that Americans are...
Related Articles
By Nick Paul Taylor, BioSpace | 03.14.2024
A U.K. watchdog balked at the cost-effectiveness of Vertex Pharmaceuticals’ CRISPR-based sickle cell disease therapy Thursday, recommending against funding the treatment unless uncertainties can be cleared up satisfactorily.
The U.K. became the first country to authorize Vertex’s Casgevy (exagamglogene...
By Anna Collinson, Maryam Ahmed and Bella McShane, BBC | 03.12.2024
Women who freeze their eggs are being misled by some UK clinics about their chances of having a baby, a fertility charity says.
The Fertility Network was reacting to BBC analysis that found 41% of clinics offering the service privately...
By Isabelle Bartram, Guest Contributor
| 03.13.2024
Note: This article was originally published in February 2024 in issue 268 of the German-language journal Der Gen-ethische Informationsdienst (GID). It is also part of an English-language dossier on Heritable Human Genome Editing published at the same time. Minor edits have been made.
Calls for German embryo research
Pressure on the German Embryo Protection Act is growing. The scientific community is launching a renewed attack on the controversial law and demands access to embryos for so-called high-ranking research objectives. "Germline therapies" are...
By Andrew Joseph, STAT | 02.22.2024
In the years leading up to Russia’s invasion, Ukraine had become a burgeoning hub of clinical trials, particularly in oncology. The war put a hold on the vast majority of those studies.
But as the country marks two years this...